MEDP

Medpace Holdings Inc
NASDAQHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$16.15B
P/E Ratio
34.05
EPS
$16.99
Beta
1.15
52W High
$677.90
52W Low
$373.00
50-Day MA
$534.15
200-Day MA
$519.85
Dividend Yield
Profit Margin
17.70%
Forward P/E
33.67
PEG Ratio
3.09

About Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$2.78B
Gross Profit (TTM)$2.01B
EBITDA$611.20M
Operating Margin20.80%
Return on Equity162.10%
Return on Assets20.10%
Revenue/Share (TTM)$98.47
Book Value$15.54
Price-to-Book37.19
Price-to-Sales (TTM)5.80
EV/Revenue5.66
EV/EBITDA25.77
Quarterly Earnings Growth (YoY)37.10%
Quarterly Revenue Growth (YoY)17.20%
Shares Outstanding$27.91M
Float$22.38M
% Insiders19.75%
% Institutions91.62%

Historical Volatility

HV 10-Day
27.69%
HV 20-Day
55.60%
HV 30-Day
48.45%
HV 60-Day
41.35%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($581.83 target)
1
Strong Buy
3
Buy
8
Hold
1
Sell

Latest News

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research8/10/2026Positive
Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning the Company's backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio.

PRNewsWire8/10/2026Neutral
Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?

Medpace Holdings, Inc. (MEDP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks Investment Research8/7/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MEDP and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026